The Association of Statin Therapy with Liver and Pancreatic Fat Fraction in Type 2 Diabetes Mellitus
<b>Background/Objectives</b>: It has been shown that the use of statins in patients with type 2 diabetes mellitus (T2DM) worsens hyperglycemia and hemoglobin A1c levels but may help in the preservation of pancreatic β-cell function. The potential role of a high pancreatic fat fraction (P...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/15/4/426 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850082176374145024 |
|---|---|
| author | Mehmet Akif Parlar Hakan Mutlu Betül Doğantekin İsmail Serhat Musaoğlu Nisa Demirboşnak Albayrakoğlu Mustafa Lütfi Yavuz Zehra Buşra Özbolat Mustafa Kaplan |
| author_facet | Mehmet Akif Parlar Hakan Mutlu Betül Doğantekin İsmail Serhat Musaoğlu Nisa Demirboşnak Albayrakoğlu Mustafa Lütfi Yavuz Zehra Buşra Özbolat Mustafa Kaplan |
| author_sort | Mehmet Akif Parlar |
| collection | DOAJ |
| description | <b>Background/Objectives</b>: It has been shown that the use of statins in patients with type 2 diabetes mellitus (T2DM) worsens hyperglycemia and hemoglobin A1c levels but may help in the preservation of pancreatic β-cell function. The potential role of a high pancreatic fat fraction (PFF) in this process has not yet been clarified. This study aimed to investigate whether the liver fat fraction (LFF) and PFF in T2DM patients is affected by statin therapy. <b>Methods</b>: This cross-sectional study involved a total of 140 T2DM patients, including both those who were receiving (n = 70) and those who were not receiving (n = 70) statin therapy. The mapping of the LFF and PFF utilizing the IDEAL-IQ sequence was conducted in magnetic resonance imaging. <b>Results</b>: In T2DM patients who used statins, the median PFF was higher compared to those who did not use statins (8.4 vs. 6.2%, <i>p</i> = 0.021), while the median LFF was found to be similar (8.4 vs. 8.9, <i>p</i> = 0.572). Variations in PFF were associated with the use of various statins (non-statin group: 6.2 vs. atovastatin: 8.7 vs. rosuvastatin: 3.2 vs. pitavastatin: 9.2, <i>p</i> = 0.004). The multivariable regression analysis indicated that insulin usage decreased log(LFF) by a factor of 0.16-fold (ꞵ ± SE = −0.16 ± 0.05, <i>p</i> = 0.010), and rosuvastatin usage reduced log(PFF) by 0.16-fold (ꞵ ± SE = −0.16 ± 0.07, <i>p</i> = 0.025), irrespective of other risk factors. Furthermore, the use of atorvastatin (ꞵ ± SE = 0.17 ± 0.06, <i>p</i> = 0.011) and pitavastatin (ꞵ ± SE = 0.19 ± 0.07, <i>p</i> = 0.008) were independently associated with an increase in log(PFF). <b>Conclusions</b>: In patients with T2DM, statin use did not show a significant effect on the liver fat fraction, but it caused differences in the pancreatic fat fraction. The observation of a lower pancreatic fat fraction in patients taking a rosuvastatin and atorvastatin dose of 40 mg/day suggests that different types and doses of statins may have varying effects on pancreatic fat accumulation. |
| format | Article |
| id | doaj-art-0fd1faa0d5b04b55b95bae8b92b5966c |
| institution | DOAJ |
| issn | 2075-4418 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj-art-0fd1faa0d5b04b55b95bae8b92b5966c2025-08-20T02:44:35ZengMDPI AGDiagnostics2075-44182025-02-0115442610.3390/diagnostics15040426The Association of Statin Therapy with Liver and Pancreatic Fat Fraction in Type 2 Diabetes MellitusMehmet Akif Parlar0Hakan Mutlu1Betül Doğantekin2İsmail Serhat Musaoğlu3Nisa Demirboşnak Albayrakoğlu4Mustafa Lütfi Yavuz5Zehra Buşra Özbolat6Mustafa Kaplan7Department of Internal Medicine, Sultan 2. Abdülhamid Han Training and Research Hospital, University of Health Sciences, Selimiye Neighborhood, Tıbbiye Street, 34668 Istanbul, TurkeyDepartment of Internal Medicine, Sultan 2. Abdülhamid Han Training and Research Hospital, University of Health Sciences, Selimiye Neighborhood, Tıbbiye Street, 34668 Istanbul, TurkeyDepartment of Internal Medicine, Sultan 2. Abdülhamid Han Training and Research Hospital, University of Health Sciences, Selimiye Neighborhood, Tıbbiye Street, 34668 Istanbul, TurkeyDepartment of Internal Medicine, Sultan 2. Abdülhamid Han Training and Research Hospital, University of Health Sciences, Selimiye Neighborhood, Tıbbiye Street, 34668 Istanbul, TurkeyDepartment of Internal Medicine, Sultan 2. Abdülhamid Han Training and Research Hospital, University of Health Sciences, Selimiye Neighborhood, Tıbbiye Street, 34668 Istanbul, TurkeyDepartment of Cardiology, Istanbul University Faculty of Medicine, 34093 Istanbul, TurkeyDeparment of Chest Diseases, Çerkezköy State Hospital, Tekirdağ Provincial Health Directorate, 59100 Tekirdağ, TurkeyDepartment of Internal Medicine, Sultan 2. Abdülhamid Han Training and Research Hospital, University of Health Sciences, Selimiye Neighborhood, Tıbbiye Street, 34668 Istanbul, Turkey<b>Background/Objectives</b>: It has been shown that the use of statins in patients with type 2 diabetes mellitus (T2DM) worsens hyperglycemia and hemoglobin A1c levels but may help in the preservation of pancreatic β-cell function. The potential role of a high pancreatic fat fraction (PFF) in this process has not yet been clarified. This study aimed to investigate whether the liver fat fraction (LFF) and PFF in T2DM patients is affected by statin therapy. <b>Methods</b>: This cross-sectional study involved a total of 140 T2DM patients, including both those who were receiving (n = 70) and those who were not receiving (n = 70) statin therapy. The mapping of the LFF and PFF utilizing the IDEAL-IQ sequence was conducted in magnetic resonance imaging. <b>Results</b>: In T2DM patients who used statins, the median PFF was higher compared to those who did not use statins (8.4 vs. 6.2%, <i>p</i> = 0.021), while the median LFF was found to be similar (8.4 vs. 8.9, <i>p</i> = 0.572). Variations in PFF were associated with the use of various statins (non-statin group: 6.2 vs. atovastatin: 8.7 vs. rosuvastatin: 3.2 vs. pitavastatin: 9.2, <i>p</i> = 0.004). The multivariable regression analysis indicated that insulin usage decreased log(LFF) by a factor of 0.16-fold (ꞵ ± SE = −0.16 ± 0.05, <i>p</i> = 0.010), and rosuvastatin usage reduced log(PFF) by 0.16-fold (ꞵ ± SE = −0.16 ± 0.07, <i>p</i> = 0.025), irrespective of other risk factors. Furthermore, the use of atorvastatin (ꞵ ± SE = 0.17 ± 0.06, <i>p</i> = 0.011) and pitavastatin (ꞵ ± SE = 0.19 ± 0.07, <i>p</i> = 0.008) were independently associated with an increase in log(PFF). <b>Conclusions</b>: In patients with T2DM, statin use did not show a significant effect on the liver fat fraction, but it caused differences in the pancreatic fat fraction. The observation of a lower pancreatic fat fraction in patients taking a rosuvastatin and atorvastatin dose of 40 mg/day suggests that different types and doses of statins may have varying effects on pancreatic fat accumulation.https://www.mdpi.com/2075-4418/15/4/426diabetes mellitusfatty pancreasfatty liverstatinsteatosis |
| spellingShingle | Mehmet Akif Parlar Hakan Mutlu Betül Doğantekin İsmail Serhat Musaoğlu Nisa Demirboşnak Albayrakoğlu Mustafa Lütfi Yavuz Zehra Buşra Özbolat Mustafa Kaplan The Association of Statin Therapy with Liver and Pancreatic Fat Fraction in Type 2 Diabetes Mellitus Diagnostics diabetes mellitus fatty pancreas fatty liver statin steatosis |
| title | The Association of Statin Therapy with Liver and Pancreatic Fat Fraction in Type 2 Diabetes Mellitus |
| title_full | The Association of Statin Therapy with Liver and Pancreatic Fat Fraction in Type 2 Diabetes Mellitus |
| title_fullStr | The Association of Statin Therapy with Liver and Pancreatic Fat Fraction in Type 2 Diabetes Mellitus |
| title_full_unstemmed | The Association of Statin Therapy with Liver and Pancreatic Fat Fraction in Type 2 Diabetes Mellitus |
| title_short | The Association of Statin Therapy with Liver and Pancreatic Fat Fraction in Type 2 Diabetes Mellitus |
| title_sort | association of statin therapy with liver and pancreatic fat fraction in type 2 diabetes mellitus |
| topic | diabetes mellitus fatty pancreas fatty liver statin steatosis |
| url | https://www.mdpi.com/2075-4418/15/4/426 |
| work_keys_str_mv | AT mehmetakifparlar theassociationofstatintherapywithliverandpancreaticfatfractionintype2diabetesmellitus AT hakanmutlu theassociationofstatintherapywithliverandpancreaticfatfractionintype2diabetesmellitus AT betuldogantekin theassociationofstatintherapywithliverandpancreaticfatfractionintype2diabetesmellitus AT ismailserhatmusaoglu theassociationofstatintherapywithliverandpancreaticfatfractionintype2diabetesmellitus AT nisademirbosnakalbayrakoglu theassociationofstatintherapywithliverandpancreaticfatfractionintype2diabetesmellitus AT mustafalutfiyavuz theassociationofstatintherapywithliverandpancreaticfatfractionintype2diabetesmellitus AT zehrabusraozbolat theassociationofstatintherapywithliverandpancreaticfatfractionintype2diabetesmellitus AT mustafakaplan theassociationofstatintherapywithliverandpancreaticfatfractionintype2diabetesmellitus AT mehmetakifparlar associationofstatintherapywithliverandpancreaticfatfractionintype2diabetesmellitus AT hakanmutlu associationofstatintherapywithliverandpancreaticfatfractionintype2diabetesmellitus AT betuldogantekin associationofstatintherapywithliverandpancreaticfatfractionintype2diabetesmellitus AT ismailserhatmusaoglu associationofstatintherapywithliverandpancreaticfatfractionintype2diabetesmellitus AT nisademirbosnakalbayrakoglu associationofstatintherapywithliverandpancreaticfatfractionintype2diabetesmellitus AT mustafalutfiyavuz associationofstatintherapywithliverandpancreaticfatfractionintype2diabetesmellitus AT zehrabusraozbolat associationofstatintherapywithliverandpancreaticfatfractionintype2diabetesmellitus AT mustafakaplan associationofstatintherapywithliverandpancreaticfatfractionintype2diabetesmellitus |